Reviewing the role of progesterone therapy in endometriosis

References

• Vercellini P, Somigliana E, Viganò P, et al. Endometriosis: current therapies and new pharmacological developments. Drugs 2009;69: 649–675.
   PubMed Web of Science ®Google Scholar
• Pankratjevaite L, Samiatina-Morkuniene D. A case report of thoracic endometriosis – a rare cause of haemothorax. Int J Surg Case Rep. 2017;33:139–142.
   PubMed Web of Science ®Google Scholar
• Angioni S, Cofelice V, Sedda F, et al. Progestins for symptomatic endometriosis: results of clinical studies. Curr Drug Ther. 2015;10: 91–104.
   Web of Science ®Google Scholar
• Jones CJP, Inuwa IM, Nardo LG, et al. Eutopic endometrium from women with endometriosis shows altered ultrastructure and glycosylation compared to that from healthy controls—a pilot observational study. Reprod Sci. 2009;16:559–572.
   PubMed Web of Science ®Google Scholar
• Locci R, Nisolle M, Angioni S, et al. Expression of the gamma 2 chain of laminin-332 in eutopic and ectopic endometrium of patients with endometriosis. Reprod Biol Endocrinol. 2013;11:94.
   PubMed Web of Science ®Google Scholar
• Kitawaki J, Kado N, Ishihara H, et al. Endometriosis: the pathophysiology as an estrogen-dependent disease. J Steroid Biochem Mol Biol. 2002;83:149–155.
   PubMed Web of Science ®Google Scholar
• Zeitoun K. Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol. J Clin Endocrinol Metabol. 1998;83:4474–4480.
   PubMed Web of Science ®Google Scholar
• Noble LS. Prostaglandin E2 Stimulates Aromatase Expression in Endometriosis-Derived Stromal Cells*. J Clin Endocrinol Metabol. 1997;82:600–606.
   PubMed Web of Science ®Google Scholar
• Fu J, Song H, Zhou M, et al. Progesterone receptor modulators for endometriosis. Cochrane Database Syst Rev. 2017;7:CD009881.
   PubMedGoogle Scholar
• Wu L, Einstein M, Geissler WM, et al. Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. J Biol Chem. 1993;268:12964–12969.
   PubMed Web of Science ®Google Scholar
• Rousseau-Merck MF, Misrahi M, Loosfelt H, et al. Localization of the human progesterone receptor gene to chromosome 11q22–q23. Hum Genet. 1987;77:280–282.
   PubMed Web of Science ®Google Scholar
• Kastner P, Krust A, Turcotte B, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J. 1990;9:1603.
   PubMed Web of Science ®Google Scholar
• Horwitz KB, Alexander PS. In situ photolinked nuclear progesterone receptors of human breast cancer cells: subunit molecular weights after transformation and translocation. Endocrinology 1983;113:2195–2201.
   PubMed Web of Science ®Google Scholar
• Alexander IE, Clarke CL, Shine J, et al. Progestin Inhibition of Progesterone Receptor Gene Expression in Human these steroids is determined in part by the cellular Breast Cancer Cells. Mol Endocrinol. 1989;3:1377–1386.
   PubMedGoogle Scholar
• Lessey BA, Sue Alexander P, Horwitz KB. The subunit structure of human breast cancer progesterone receptors: characterization by chromatography and photoaffinity labeling. Endocrinology 1983;112:1267–1274.
   PubMed Web of Science ®Google Scholar
• Conneely OM, Sullivan WP, Toft DO, et al. Molecular cloning of the chicken progesterone receptor. Science 1986;233:767–771.
   PubMed Web of Science ®Google Scholar
• Giangrande PH, McDonnell DP. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog Hormone Res. 1998;54:291–313.
   Google Scholar
• Attia GR. Progesterone receptor isoform A but not B is expressed in endometriosis 1. J Clin Endocrinol Metabol. 2000;85:2897–2902.
   PubMed Web of Science ®Google Scholar
• Bulun SE. Endometriosis. N Engl J Med. 2009;360:268–279.
   PubMed Web of Science ®Google Scholar
• Reis FM, Petraglia F, Taylor RN. Endometriosis: hormone regulation and clinical consequences of chemotaxis and apoptosis. Hum Reprod Update. 2013;19:406–418.
   PubMed Web of Science ®Google Scholar
• Han SJ, O'Malley BW. The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis. Hum Reprod Update. 2014;20:467.
   PubMed Web of Science ®Google Scholar
• Joshi NR, et al. Progesterone resistance in endometriosis is modulated by the altered expression of MicroRNA-29c and FKBP4. J Clin Endocrinol Metabol. 2017;102:141–149.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Pietropaolo G, De Giorgi O, et al. Treatment of symptomatic rectovaginal endometriosis with an estrogen–progestogen combination versus low-dose norethindrone acetate. Fertil Steril. 2005;84:1375–1387.
   PubMed Web of Science ®Google Scholar
• Bergqvist A, Theorell T. Changes in quality of life after hormonal treatment of endometriosis. Acta Obstet Gynecol Scand. 2001;80:628–637.
   PubMed Web of Science ®Google Scholar
• Morotti M, Venturini PL, Biscaldi E, et al. Efficacy and acceptability of long-term norethindrone acetate for the treatment of rectovaginal endometriosis. Eur J Obstetr Gynecol Reprod Biol. 2017;213:4–10.
   PubMed Web of Science ®Google Scholar
• Taniguchi F, Enatsu A, Ikebuchi A, et al. Efficacy of norethisterone in patients with ovarian endometrioma. Yonago Acta Med. 2017;60:182–185.
   PubMed Web of Science ®Google Scholar
• Lee D-Y, Lee J-Y, Seo J-W, et al. Gonadotropin-releasing hormone agonist with add-back treatment is as effective and tolerable as dienogest in preventing pain recurrence after laparoscopic surgery for endometriosis. Arch Gynecol Obstet. 2016;294:1257–1263.
   PubMed Web of Science ®Google Scholar
• Harrison RF, Barry-Kinsella C. Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertil Steril. 2000;74:24–30.
   PubMed Web of Science ®Google Scholar
• Tsai H-W, Wang P-H, Huang B-S, et al. Low-dose add-back therapy during postoperative GnRH agonist treatment. Taiwanese J Obstetr Gynecol. 2016;55:55–59.
   PubMed Web of Science ®Google Scholar
• Vercellini P, De Giorgi O, Mosconi P, et al. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril. 2002;77:52–61.
   PubMed Web of Science ®Google Scholar
• Hayashi A, Tanabe A, Kawabe S, et al. Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis. J Ovarian Res. 2012;5:31.
   PubMed Web of Science ®Google Scholar
• Harada T, Momoeda M, Taketani Y, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis—a randomized, double-blind, multicenter, controlled trial. Fertil Steril. 2009;91:675–681.
   PubMed Web of Science ®Google Scholar
• Köhler G, Faustmann TA, Gerlinger C, et al. A dose‐ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis. Int J Gynecol Obstetr. 2010;108:21–25.
   PubMed Web of Science ®Google Scholar
• Strowitzki T, Faustmann T, Gerlinger C, et al. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. Eur J Obstetr Gynecol Reprod Biol. 2010;151:193–198.
   PubMed Web of Science ®Google Scholar
• Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25:633–641.
   PubMed Web of Science ®Google Scholar
• Strowitzki T, Marr J, Gerlinger C, et al. Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. Int J Gynecol Obstetr. 2012;117:228–233.
   PubMed Web of Science ®Google Scholar
• Petraglia F, Hornung D, Seitz C, et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet. 2012;285:167–173.
   PubMed Web of Science ®Google Scholar
• Maiorana A, et al. Efficacy of dienogest in improving pain in women with endometriosis: a 12-month single-center experience. Arch Gynecol Obstet. 2017;296:429–433.
   PubMed Web of Science ®Google Scholar
• Lang J, et al. Dienogest for treatment of endometriosis in chinese women: a placebo-controlled, randomized, double-blind phase 3 study. J Women's Health. 2018;27:148–155.
   PubMed Web of Science ®Google Scholar
• Momoeda M, Taketani Y, Terakawa N, et al. A randomized, double-blind, multicenter, parallel, dose-response study of dienogest in patients with endometriosis. Jpn Pharmacol Therapeut. 2007;35:769.
   Google Scholar
• Harada M, Osuga Y, Izumi G, et al. Dienogest, a new conservative strategy for extragenital endometriosis: a pilot study. Gynecol Endocrinol. 2011;27:717–720.
   PubMed Web of Science ®Google Scholar
• Leonardo-Pinto JP, Benetti-Pinto CL, Cursino K, et al. Dienogest and deep infiltrating endometriosis: The remission of symptoms is not related to endometriosis nodule remission. Eur J Obstetr Gynecol Reprod Biol. 2017;211:108–111.
   PubMed Web of Science ®Google Scholar
• Yamanaka A, Hada T, Matsumoto T, et al. Effect of dienogest on pain and ovarian endometrioma occurrence after laparoscopic resection of uterosacral ligaments with deep infiltrating endometriosis. Eur J Obstetr Gynecol Reprod Biol. 2017;216:51–55.
   PubMed Web of Science ®Google Scholar
• Seo J-W, Lee D-Y, Yoon B-K, et al. Effects of long-term postoperative dienogest use for treatment of endometriosis on bone mineral density. Eur J Obstetr Gynecol Reprod Biol. 2017;212:9–12.
   PubMed Web of Science ®Google Scholar
• Ebert AD, Dong L, Merz M, et al. Dienogest 2 mg daily in the treatment of adolescents with clinically suspected endometriosis: the VISanne study to assess safety in ADOlescents. J Pediatr Adolesc Gynecol. 2017;30:560–567.
   PubMed Web of Science ®Google Scholar
• Rižner TL, Brožič P, Doucette C, et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids 2011;76:607–615.
   PubMed Web of Science ®Google Scholar
• Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003;46:7–16.
   PubMed Web of Science ®Google Scholar
• Tumasian KP, Bespoiasnaia VV, Voronovskaia IV. Treatment of endometriosis in female infertility. Likars' Ka Sprava/Ministerstvo Okhorony Zdorov'ia Ukrainy. 2000;3:103–105.
   Google Scholar
• Overton CE, Lindsay PC, Johal B, et al. A randomized, double-blind, placebo-controlled study of luteal phase dydrogesterone (Duphaston) in women with minimal to mild endometriosist. Fertil Steril. 1994;62:701–707.
   PubMed Web of Science ®Google Scholar
• Trivedi P, Selvaraj K, Mahapatra PD, et al. Effective post-laparoscopic treatment of endometriosis with dydrogesterone. Gynecol Endocrinol. 2007;23:73–76.
   PubMed Web of Science ®Google Scholar
• Zou S, et al. Oral continuous combined 0.5 mg estradiol valerate and 5 mg dydrogesterone as daily add-back therapy during post-operative GnRH agonist treatment for endometriosis in Chinese women. Int J Clin Exp Med. 2013;6:67–73.
   PubMed Web of Science ®Google Scholar
• Crosignani PG, Luciano A, Ray A, et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod. 2006;21:248–256.
   PubMed Web of Science ®Google Scholar
• Vercellini P, De Giorgi O, Oldani S, et al. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. Am J Obstet Gynecol. 1996;175:396–401.
   PubMed Web of Science ®Google Scholar
• Carr B, Dmowski WP, O’Brien C, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014;21:1341–1351.
   PubMed Web of Science ®Google Scholar
• Cheewadhanaraks S. Cumulative recurrence rates of endometriosis-associated pain after long-term intramuscular depot medroxyprogesterone acetate therapy. J Med Assoc Thai. 2013;96:140–143.
   PubMedGoogle Scholar
• Walch K, Unfried G, Huber J, et al. Implanon® versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis—a pilot study. Contraception 2009;79:29–34.
   PubMed Web of Science ®Google Scholar
• Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon®. Contraception 1998;58:99S–107S.
   PubMed Web of Science ®Google Scholar
• Beerthuizen R, van Beek A, Massai R, et al. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon® compared to a non-hormonal method of contraception. Hum Reprod. 2000;15:118–122.
   PubMed Web of Science ®Google Scholar
• Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, et al. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trial. Obstet Gynecol. 2012;119:519–526.
   PubMed Web of Science ®Google Scholar
• Vercellini P, Viganò P, Somigliana E. The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis. Curr Opin Obstetr Gynecol. 2005;17:359–365.
   PubMed Web of Science ®Google Scholar
• Lockhat FB, Emembolu JO, Konje JC. The evaluation of the effectiveness of an intrauterine‐administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease. Hum Reprod. 2004;19:179–184.
   PubMed Web of Science ®Google Scholar
• Matorras R, et al. Efficacy of the levonorgestrel-releasing intrauterine device in the treatment of recurrent pelvic pain in multitreated endometriosis. J Reprod Med. 2010;56:497–503.
   Web of Science ®Google Scholar
• Lockhat FB, Emembolu JO, Konje JC. The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. Hum Reprod. 2005;20:789–793.
   PubMed Web of Science ®Google Scholar
• Bayoglu Tekin Y, Dilbaz B, Altinbas SK, et al. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril. 2011;95:492–496.
   PubMed Web of Science ®Google Scholar
• de Sá Rosa e Silva ACJ, Rosa e Silva JC, Nogueira AA, et al. The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis. Fertil Steril. 2006;86:742–744.
   PubMed Web of Science ®Google Scholar
• Li T, et al. Efficacy and impact on quality of life of different drug treatments after partial resection of rectovaginal endometriosis. Zhonghua Fu Chan Ke Za Zhi. 2017;52:307.
   PubMedGoogle Scholar
• Chen Y-J, et al. Postoperative maintenance levonorgestrel-releasing intrauterine system and endometrioma recurrence: a randomized controlled study. Am J Obstetr Gynecol. 2017;216:582.e1–582.e9.
   PubMed Web of Science ®Google Scholar
• Kim MK, Chon SJ, Lee JH, et al. Postoperative levonorgestrel-releasing intrauterine system insertion after gonadotropin-releasing hormone agonist treatment for preventing endometriotic cyst recurrence: a prospective observational study. Reprod Sci. 2018;25:39–43.
   PubMed Web of Science ®Google Scholar
• Cho S, Jung JA, Lee Y, et al. Postoperative levonorgestrel-releasing intrauterine system versus oral contraceptives after gonadotropin-releasing hormone agonist treatment for preventing endometrioma recurrence. Acta Obstet Gynecol Scand. 2014;93:38–44.
   PubMed Web of Science ®Google Scholar
• Morelli M, Sacchinelli A, Venturella R, et al. Postoperative administration of dienogest plus estradiol valerate versus levonorgestrel-releasing intrauterine device for prevention of pain relapse and disease recurrence in endometriosis patients. J Obstet Gynaecol Res. 2013;39:985–990.
   PubMed Web of Science ®Google Scholar